Andrew M. Scharenberg is an Entrepreneur Partner at MPM BioImpact and founder and CEO of portfolio company Umoja Biopharma. Before founding Umoja, Andrew was an attending physician at Seattle Children’s Hospital and a professor in the Department of Pediatrics and adjunct professor in the Department of Immunology.
Brendan is the chief compliance officer of MPM BioImpact. Before joining MPM, he was a senior principal consultant at ACA Group, supporting hedge, private equity, and venture capital funds with custom compliance programs.
David Kolesky is a principal at MPM BioImpact, driving investments and company creation. Previously, he was a principal at Flagship Pioneering and co-founded Senda Biosciences and Montai Health.
Dr. Grey Sieczkiewicz serves as IP counsel to several MPM BioImpact portfolio companies. Previously, he developed IP strategies for more than a dozen venture-backed life sciences companies, including in nucleic acid therapeutics, oral biologics, the microbiome, oncology, and protein engineering.